Saltar al contenido principal

ETHNOS_APP

Inicio • Búsqueda • Revistas • Lista 0

Are Elderly Patients With Clinically Localized Prostate Cancer Overtreated? Exploring Heterogeneity in Survival Effects

Datos Bibliográficos

ID9102352
AutoresAnirban Basu (0000-0001-6620-8320, autor de correspondencia), John L Gore (0000-0002-2847-5062, University of Washington)
Año2015
Volumen53
Número1
Páginas79-86
Fecha de publicación2015-01-01
Peer ReviewedSí
Open AccessNo
TipoARTICLE
RevistaMedical Care (JOURNAL)
Identificadores de la revistaISSN: 0025-7079 • E-ISSN: 1537-1948
EditorialOvid Technologies (Wolters Kluwer Health) (PUBLISHER)
DOI10.1097/mlr.0000000000000260
PMID25397964
OpenAlexW2312509683
IdiomaEN
Referencias citadas22

BACKGROUND: Clinical trial evidence shows minimal survival gains and higher complication rates from radical prostatectomy (RP) versus watchful waiting (WW) for elderly men with localized prostate cancer (PCa). It is believed that these patients are overtreated. The current analyses aim to explore patient-level heterogeneity in survival effects, examine matching of patients to treatments in practice, and identify patient characteristics driving heterogenous effects, in order to present more comprehensive evidence about the concerns of overtreatment. METHODS: Eleven-year all-cause and PCa-specific survival among SEER-Medicare patients diagnosed during 1996-2002 were analyzed using local instrumental variable approaches. RESULTS: A total of 8462 (77%) of 11,036 patients received RP. The average effects of RP over WW on 11-year overall and cancer-specific survival were 1.1 months (95%CI, -25, 28; P=0.94) and 1.7 months (95%CI, -25, 29; P=0.90) respectively; effects did not differ significantly according to age, race, grade, and stage. Fewer than 1% of patients had significant cancer-specific survival benefit from RP at the 10% level; 6% were expected to gain over 15 months from RP. However, patients with larger expected survival gains from RP were much more likely to receive RP in practice. Such positive self-selection was driven by PCa-specific survival than overall survival. Several comorbidities may play a critical role in predicting who could benefit from RP. CONCLUSIONS: Our analyses corroborate concerns about PCa overtreatment. A small fraction of screen-detected PCa patients derive survival benefits from RP. Prediction tools should account for patient comorbidities to accurately predict survival benefits of RP over WW

Cancer · Overall survival · Proportional hazards model · Prostate cancer · Prostatectomy · Stage (stratigraphy) · Watchful waiting · Cancer survivorship and care · Internal Medicine · Medicine · Oncology · Prostate Cancer Diagnosis and Treatment · Prostate Cancer Treatment and Research · Surgery

  • Structural Equations, Treatment Effects, and Econometric Policy Evaluation1

    Open Access•James J Heckman, Edward Vytlacil•Econometrica•2005

  • Local instrumental variables and latent variable models for identifying and bounding treatment effects

    Open Access•James J Heckman, Edward Vytlacil et al.•Proceedings of the National…•1999

  • Studying Radiation Therapy Using Seer-Medicare-Linked Data

    Beth A Virnig, Joan L Warren et al.•Medical Care•2002

  • Use of Seer-Medicare Data for Measuring Cancer Surgery

    Gregory S Cooper, Beth A Virnig et al.•Medical Care•2002

Velocidad de citaciónhistorical
Altamente citadoNo
Ethnos_APP • Proyecto Open Source • Licencia MIT • Frontend v2.0.0 • Privacidad y Cookies • Documentación de la API: api.ethnos.app/docs • Código de la API: GitHub • DOI: 10.5281/zenodo.17049435 • Código del Frontend: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae